NanoViricides Develops Drug Candidates Against CoronaVirus
An American antiviral therapy company, NanoViricides, has been working on developing drug candidates that has proven to have a high anti-viral effectiveness in different studies against different strains of coronavirus.
Two of these cases were tested against cell cultures that infect humans. The human coronavirus tested on is similar to SARS-CoV-2 that causes Covid-19. It is more-mild than SARS-CoV-2, so the researchers think this is a good surrogate model to test their drugs against. In more testing, it was found that these two nanoviricides drug candidates were highly effective against another coronavirus – hCoV-229E. This is what causes the common cold for humans. NanoViricides belives that because these drugs have tested so well against other Coronaviruses, they have a strong chance at developing an effective antiviral drug against the strain causing Covid-19.
These drugs have not yet been studied on humans and have no FDA approval for clinical testing. They are in their early stages of development, and the company wants to continue studying them before applying for human trials.